The Extraordinary But Uncertain Growth Of The COVID-19 Market

Q1 Sales Of Leading Products

The value of the COVID-19 market reached more than $8bn in the first quarter, fuelled by mRNA-based vaccines, but the future growth of the sector depends on the rather unpredictable course of the pandemic, and the response of healthcare providers and countries.  

covid injection
• Source: Alamy

The value of the COVID-19 market reached at least $8.5bn in the first quarter of 2021 for major pharmaceutical and biotech companies, an extraordinary amount, and its value is expected to increase, for vaccines alone, to nearly 10 times that amount in the full year.

Among a selected group of major pharmaceutical and biotech companies, the mRNA COVID-19 vaccines from Pfizer Inc./BioNTech SE and Moderna, Inc. achieved the highest amount of sales during the first quarter, with Gilead Sciences, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.